Mumbai, Jan 19 : Pharmaceuticals firm Lupin Today  said it has partnered with Shenzhen Foncoo Pharmaceutical, to cater to the Chinese healthcare market.

This is Lupin’s first partnership arrangement in China and reinforces Lupin’s commitment to bringing high quality generic and complex generic medicines to patients around the world, the company said in a statement.

“Lupin continues to invest in key growth markets. With China’s growing commitment to affordable and accessible healthcare, Lupin is committed to serving the healthcare needs of the Chinese population by providing high quality generic and complex generic products. We are very excited about our partnership with Foncoo,” Lupin President – Growth Markets Dr. Fabrice Egros said.

He further said that the company will continue to explore additional partnership opportunities in China to leverage its global portfolio including complex generics and specialty medicines.

The Mumbai headquartered company develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the US, India, South Africa, and across the Asia Pacific, Latin America, Europe, and Middle East regions.

Commenting on the partnership, Foncoo General Manager Peng Yan said, “Foncoo’s successful experiences on importing registration and marketing of the generic formulations and Lupin’s strong capability of making high-quality medicines make us perfect match to each other and our collaboration will have a bright future most likely. We expect that the successful launch of our first product in China will come smoothly and soon.”

He noted that the company will also continue to explore more opportunities to work with Lupin for providing more and more high-valued and complex medicines to the Chinese physicians and patients.

Shenzhen Foncoo Pharmaceutical specializes in providing pharmaceutical products that treat central nervous system disorders.(UNI)